Table 1.
Baseline characteristics by treatment arm
| CMT (n = 120) | STLI (n = 119) | P value | |
|---|---|---|---|
| Sex | .94 | ||
| Female | 43 % | 42 % | |
| Male | 57 % | 58 % | |
| Mean age (range) | 35.1 (17–71) | 35.5 (18–85) | .78 |
| Performance status | .34 | ||
| 0 | 91 % | 94 % | |
| 1 | 9 % | 6 % | |
| 2 | 0 % | 0 % | |
| Involved lymph node sites | .85 | ||
| 0–1 | 33 % | 34 % | |
| ≥2 | 66 % | 66 % | |
| Histology | .97 | ||
| NS/LP | 81 % | 81 % | |
| Other | 19 % | 19 % | |
| High neck presentation | .62 | ||
| Yes | 77 % | 74 % | |
| No | 23 % | 26 % | |
| Type of disease | .62 | ||
| NED | 9 % | 8 % | |
| Bidimensionally measurable | 83 % | 82 % | |
| Assessable | 8 % | 11 % | |
| Lymphangiogram performed | .31 | ||
| Yes | 17 % | 22 % | |
| No | 83 % | 78 % | |
| Mean vitality total score | 55.0 | 59.5 | .13 |
| Mean CARES physical score | 0.54 | 0.52 | .74 |
| Mean SDS total score | 20.5 | 19.8 | .27 |
CMT combined-modality treatment, STLI subtotal lymphoid irradiation, NS nodular sclerosis, LP lymphocyte predominant, NED no evidence of disease, CARES Cancer Rehabilitation Evaluation System-Short Form, SDS symptom distress scale